Meeting
2020 ASCO Virtual Scientific Program
A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Authors
Elizabeth J. Adams
Ohio State University Wexner Medical Center, Columbus, OH
Elizabeth J. Adams , Maryam B. Lustberg , Yan Jin , Yang Li , Alex Sparreboom , Shuiying Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT04205903
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS12128)
DOI
10.1200/JCO.2020.38.15_suppl.TPS12128
Abstract #
TPS12128
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
First Author: Sun Min Lim
Poster
2023 ASCO Annual Meeting
A meta-analysis studying the utility of cryotherapy in the prevention of peripheral neuropathy in breast cancer patients receiving paclitaxel and nab-paclitaxel.
First Author: Prashanth Ashok Kumar
Poster
2023 ASCO Annual Meeting
Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
First Author: Tara L. Lin
Poster
2023 ASCO Annual Meeting
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
First Author: David S. Hong